Garth Rapeport

Garth Rapeport currently serves on the management team at RIGImmune Inc. and holds the position of Entrepreneur In Residence at F-Prime Capital since June 2020. Rapeport has been a Visiting Professor at the National Heart and Lung Institute, Imperial College London, since January 2012. Previously, Rapeport co-founded Subintro and served as CEO and co-founder of Pulmocide from August 2013 to December 2019, as well as CEO and co-founder of Respivert, Ltd. from September 2007 to July 2013. Prior experience includes a role as SVP of Respiratory Centre of Excellence Drug Discovery at GSK from 2000 to 2006 and Director at Pfizer Central Research from 1988 to 1996. Garth Rapeport's educational background includes studies at the MRC Clinical Pharmacology Unit at the University of Oxford and the University Department of Medicine, Glasgow.